Evidence map›Paper›PMID 42321177›Full record

Trial reportTranslational psychiatry2026

Discovery of a potential novel pharmacogenomic biomarker on ANK3 gene for liafensine, a triple reuptake inhibitor for treatment-resistant depression.

Wen Luo, Gang Wang, John W Whitaker, Zafrin Dhali, Hong Sun, Haiping Lu, Xiaojun Li, Tao Shi, Jinkun Zhang

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wen LuoDenovo Biopharma LLC, San Diego, CA, USA. wluo@denovobiopharma.com.ORCID http://orcid.org/0009-0003-1642-3710
Gang WangBeijing Anding Hospital, Capital Medical University, Beijing, China.ORCID http://orcid.org/0000-0003-3949-1188
John W WhitakerDenovo Biopharma LLC, San Diego, CA, USA.
Zafrin DhaliDenovo Biopharma LLC, San Diego, CA, USA.
Hong SunDenovo Biopharma LLC, San Diego, CA, USA.
Haiping LuDenovo Biopharma LLC, San Diego, CA, USA.
Xiaojun LiDenovo Biopharma LLC, San Diego, CA, USA.
Tao ShiDenovo Biopharma LLC, San Diego, CA, USA.
Jinkun ZhangDenovo Biopharma LLC, San Diego, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liafensine is a triple reuptake inhibitor targeting transporters for serotonin, norepinephrine, and dopamine for treatment-resistant depression (TRD). It did not exhibit efficacy in non-biomarker-selected TRD patients in two Phase 2b studies. We utilized the blood samples from the patients enrolled in these two studies and extracted genomic DNA to conduct a genome‑wide association study aiming to find a biomarker which can predict liafensine response. A single single-nucleotide polymorphism (SNP), rs12217173, at ANK3 gene was identified as strongly associated with treatment response to liafensine (p = 6.61 × 10

Indexed as

AnkyrinsDepressive Disorder, Treatment-ResistantBiomarkersDuloxetine HydrochlorideEscitalopramFemaleGenetic MarkersGenome-Wide Association StudyHumansMaleMiddle AgedPharmacogeneticsPolymorphism, Single NucleotideANK3 protein, humanAnkyrinsBiomarkersDuloxetine HydrochlorideEscitalopramGenetic Markers

Identifiers

PMID42321177
PMCPMC13522506

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.